- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08:00 | Ondine Biomedical - Largest Private Mexican Network Pilots Steriwave | - | RNS | ||
| Fr | Ondine Biomedical - Notification of major holdings | - | RNS | ||
| Do | Pentwater reduces stake in Ondine Biomedical to 3% | 1 | Investing.com | ||
| Do | Ondine Biomedical - Notification of major holdings - Pentwater | - | RNS | ||
| ONDINE BIOMEDICAL Aktie jetzt für 0€ handeln | |||||
| Di | Ondine Biomedical - Positive Topline Results in US Phase 3 Study | - | RNS | ||
| 30.07. | Ondine Biomedical - Major Scottish Hospital Adopts Steriwave | - | RNS | ||
| 13.07. | TRADING UPDATES: Ondine study results put back; Helix seals purchase | 1 | Alliance News | ||
| 13.07. | Ondine Biomedical - Update on US Phase 3 Pivotal Study | - | RNS | ||
| 01.07. | Ondine Biomedical - Keynote Address at 8th Annual Photodynamic Day | - | RNS | ||
| 30.06. | Ondine Biomedical - Result of AGM and voting results | - | RNS | ||
| 30.06. | Ondine Biomedical - Leeds drops SSI 78% over Mupirocin with Steriwave | - | RNS | ||
| 22.06. | Ondine Biomedical highlights progress on Lantern phase 3 study | 3 | Alliance News | ||
| 22.06. | Ondine Biomedical - Update on US Phase 3 Pivotal Study | - | RNS | ||
| 18.06. | Ondine Biomedical - Leeds Drops SSIs by 78.5% in Complex Brain Surgery | - | RNS | ||
| 08.06. | Ondine Biomedical grants stock options, RSUs and warrants | 1 | Investing.com | ||
| 08.06. | Ondine Biomedical - Grant of Options and RSUs, and Issue of Warrants | - | RNS | ||
| 04.06. | Ondine Biomedical: Strategiewechsel führt zu Umsatzwachstum und hohem Verlust | 3 | Investing.com Deutsch | ||
| 04.06. | Increased investment sees Ondine Biomedical post widened annual loss | 1 | Alliance News | ||
| 04.06. | Ondine Biomedical setzt jährliche Hauptversammlung für 30. Juni an | 1 | Investing.com Deutsch | ||
| 04.06. | Ondine Biomedical schedules annual meeting for June 30 | 1 | Investing.com |
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOAFFINITY TECHNOLOGIES | 15,170 | -0,65 % | Morning Market Movers: Ultragenyx Pharmaceutical, bioAffinity Technologies, Tilly's, Inc., Snowflake See Big Swings | BEIJING (dpa-AFX) - At 7:50 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,600 | -0,03 % | Summit Therapeutics Stock Rises 11% | ||
| TARSUS PHARMACEUTICALS | 90,84 | +0,07 % | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care | Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt's disease, a potentially blinding disease with no FDA-approved... ► Artikel lesen | |
| TYRA BIOSCIENCES | 28,650 | 0,00 % | Tyra Bio rises on upcoming mid-stage trial readout for bladder cancer drug | ||
| RECURSION PHARMACEUTICALS | 3,635 | +0,14 % | Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook? | ||
| QIAGEN | 36,340 | -0,09 % | Jury Awards 10x Genomics Millions in Patent Lawsuit Against Qiagen Unit | ||
| PRAXIS PRECISION MEDICINES | 352,42 | +0,17 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| VIR BIOTECHNOLOGY | 11,385 | 0,00 % | Vir Biotechnology, Inc.: Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026 | - Oral presentation of complete Week 96 data from the Phase 2 SOLSTICE trial in chronic hepatitis delta selected for inclusion in "Best of EASL 2026" by EASL - Poster presentation of Week 48... ► Artikel lesen | |
| VERA THERAPEUTICS | 35,890 | 0,00 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| DYNE THERAPEUTICS | 24,270 | -0,04 % | Dyne to present preclinical data on four DMD therapies | ||
| RELAY THERAPEUTICS | 19,060 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 117,48 | +0,08 % | Can KT-621 Mark a Turning Point for Kymera Therapeutics? | ||
| ALUMIS | 11,090 | -0,09 % | Alumis-Aktie: No Brainer Club feiert zweistellige Kursgewinne zum Start | Gewohnt gutes Timing: Der No Brainer Club hat auch bei Alumis im richtigen Moment zugeschlagen und blickt bereits nach einem Tag auf zweistellige Kursgewinne. Nach dem massiven Abverkauf infolge enttäuschender... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 34,140 | +0,12 % | Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%? | ||
| PARABILIS MEDICINES | 40,420 | 0,00 % | Parabilis Medicines, Inc. - 8-K, Current Report |
Das Unternehmen ONDINE BIOMEDICAL INC CDIS kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +2,88 % bei einem Aktienkurs von 0,107 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ONDINE BIOMEDICAL INC CDIS finden Sie auf Wallstreet Online.